Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review

Wynne Widiarti, Alverina Cynthia Sukmajaya, David Nugraha, Firas Farisi Alkaff*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    3 Citations (Scopus)
    96 Downloads (Pure)


    Background and aims: Cardiovascular disease is one of the main contributors for the mortality in type 2 diabetes mellitus (T2DM) patients. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had shown cardiovascular benefits which may be advantageous to reduce mortality in T2DM patients. This systematic review focused on analyzing the effects of GLP-1 RAs on cardiovascular outcomes.

    Methods: We conducted an extensive search through JSTOR, PubMed, Scopus, EBSCohost, and CENTRAL. All related studies assessing the use of GLP-1 RAs in T2DM patients from inception up to October 2020 were screened. Any cardioprotective properties as the outcomes were obtained.

    Results: A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review. The GLP-1 RAs used were either liraglutide or exenatide in combination with antihypertensive or antilipidemic drugs. All studies showed that GLP-1 RA significantly caused weight loss and improved cardiac functional capacity by increasing left ventricular ejection fraction and reducing end-systolic and end-diastolic left ventricle volume. GLP-1 RA also improved myocardial blood flow without affecting myocardial glucose uptake. However, GLP-1 RA failed to show its effect in reducing blood pressure and improving lipid profiles.

    Conclusions: Despite the limited number of studies, consistent data showed that GLP-1 RA has several cardioprotective properties. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)837-843
    Number of pages7
    JournalDiabetes & metabolic syndrome-Clinical research & reviews
    Issue number3
    Publication statusPublished - May-2021


    • Antidiabetic drugs
    • Cardioprotective agents
    • Glucagon-like Peptide-1 receptor
    • Systematic review
    • Type 2 diabetes mellitus
    • ANALOG

    Cite this